<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Foscarnet: An overview
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Foscarnet: An overview
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Foscarnet: An overview
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin Rodriguez, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kimon C Zachary, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         is principally used for the treatment of ganciclovir-resistant cytomegalovirus (CMV) infections in patients with the acquired immunodeficiency syndrome (AIDS) or in transplant recipients.
        </p>
        <p>
         The mechanisms of action, pharmacokinetics, and adverse effects will be reviewed here. Treatment of the specific clinical syndromes can be found on the appropriate topic reviews.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         (trisodium phosphonoformate) is a pyrophosphate analog. It binds reversibly near the pyrophosphate-binding site of DNA polymerase (or reverse transcriptase) without requiring further modification [
         <a href="#rid1">
          1
         </a>
         ]. After binding, the drug blocks the cleavage of the pyrophosphate moiety from deoxynucleotide triphosphates, in turn halting DNA chain elongation. Foscarnet selectively inhibits viral polymerase; inhibition of mammalian DNA polymerase requires a 100-fold greater concentration of foscarnet than that required to block cytomegalovirus (CMV) replication [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          SPECTRUM OF ACTIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         inhibits the replication, at least in vitro, of multiple herpes family viruses, hepatitis B virus, and the human immunodeficiency virus (HIV) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Clinically,
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         is employed almost exclusively to treat infections with cytomegalovirus (CMV; particularly when
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         cannot be used) [
         <a href="#rid2">
          2
         </a>
         ] and acyclovir-resistant herpes simplex virus (HSV) and varicella zoster virus (VZV). In selected cases, such as CMV encephalitis, foscarnet may be used in combination with ganciclovir. (See
         <a class="medical medical_review" href="/z/d/html/3750.html" rel="external">
          "AIDS-related cytomegalovirus neurologic disease"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         has in vitro activity against human herpesvirus 6A and 6B, and has been used in a few cases [
         <a href="#rid3">
          3
         </a>
         ]. Foscarnet is
         <strong>
          not
         </strong>
         used as an antiretroviral agent to treat HIV.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          ANTIVIRAL RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resistance testing can identify mutations that help predict the activity of
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         [
         <a href="#rid4">
          4-6
         </a>
         ]. This can be used to guide antiviral therapy, especially in patients who have failed their initial regimen.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         resistance can result from mutations in the CMV UL54 gene, which encodes the DNA polymerase that is important for viral replication. Mutations in this gene reduce antiviral affinity. UL54 mutations can emerge during therapy with foscarnet, and can also emerge in the presence of prolonged
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         exposure, after the development of UL97 mutations (which confers resistance to ganciclovir but not to foscarnet).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         is not used as an anti-HIV agent, mutations in the HIV reverse transcriptase gene may result in HIV resistance to foscarnet [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         resistance is not seen in the presence of UL97 phosphotransferase mutations (seen in cytomegalovirus) or thymidine kinase mutations (seen in herpes simplex virus or varicella-zoster virus) since foscarnet does not require intracellular phosphorylation for antiviral activity. This is in contrast to the mechanism of resistance seen with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         and
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8342.html" rel="external">
          "Ganciclovir and valganciclovir: An overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          BASIC PHARMACOKINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         has poor oral bioavailability and is therefore administered intravenously. Serum levels following a given dose can vary considerably, perhaps owing to differing equilibria resulting from foscarnet deposition in bone and cartilage [
         <a href="#rid1">
          1
         </a>
         ]. Foscarnet is not significantly metabolized and is excreted solely by the kidneys, mainly via glomerular filtration and tubular secretion; bone and cartilage uptake accounts for roughly 20 percent of administered drug [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Peak concentrations with a regimen of 60 mg/kg thrice daily or 90 mg/kg twice daily range from about 400 to 700 micromol/L [
         <a href="#rid1">
          1
         </a>
         ]. Elimination follows a three-phase pattern, with half-lives of about 1 h, 3 to 7 h, and 88 h [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Clearance decreases with impaired renal function, and dose adjustment in patients with renal insufficiency is required.
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         is cleared by hemodialysis; concentrations in patients receiving 50 mg/kg after dialysis were similar to those in patients with normal renal function receiving 90 mg/kg twice daily [
         <a href="#rid1">
          1
         </a>
         ]. A small study found vitreous concentrations roughly comparable to concomitant plasma levels [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific toxicities are somewhat difficult to measure, given that
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         is used almost exclusively in patients with significant underlying illness who are often taking multiple medications. The most important adverse effects of foscarnet are decreased renal function, electrolyte abnormalities, and infusion-related nausea. Monitoring of renal function and electrolytes is important while on foscarnet therapy.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Renal insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to the drug's manufacturer in a 1993 tabulation, 27 percent of 188 patients with AIDS receiving
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         in clinical trials experienced decreased renal function [
         <a href="#rid1">
          1,9
         </a>
         ]. This impairment is usually reversible in persons with previously normal renal function [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         appears to be directly toxic to the renal tubular cells [
         <a href="#rid10">
          10
         </a>
         ]. Although tubular damage is probably the principal factor underlying foscarnet-induced renal dysfunction, the finding of crystals in the glomerular capillaries of three patients suggests that other mechanisms may contribute [
         <a href="#rid11">
          11,12
         </a>
         ]. In one case report, a patient developed crystal nephropathy and multiorgan failure after the use of foscarnet [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         The plasma creatinine concentration usually begins to rise after 6 to 15 days, the urinalysis is relatively bland, and biopsy tissue from a few patients has revealed acute tubular necrosis [
         <a href="#rid14">
          14,15
         </a>
         ]. The primary tubular injury can also explain the frequent polyuria and polydipsia via interference with the action of antidiuretic hormone [
         <a href="#rid16">
          16
         </a>
         ]; in some cases, arginine vasopressin resistance (AVP-R; previously called nephrogenic diabetes insipidus) has occurred in the absence of an elevation in the plasma creatinine concentration [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Renal toxicity appears to be reduced by concomitant
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (generally 0.5 to 1 L) administration. Administration of other nephrotoxic drugs such as amphotericin B or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         along with
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         may increase the risk of renal insufficiency substantially [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Electrolyte abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypocalcemia is a well-established effect of
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         , possibly via complex formation between the drug and free calcium [
         <a href="#rid21">
          21
         </a>
         ]. Hypomagnesemia is also commonly found and may contribute to the development of both hypocalcemia and hypokalemia [
         <a href="#rid1">
          1,21
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion"
         </a>
         ). Other electrolyte disturbances that may occur include hypophosphatemia, hypercalcemia, and hyperphosphatemia [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seizures have been associated with
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         in AIDS clinical trials, but it is unclear whether this effect reflects direct toxicity, drug-induced hypocalcemia, or underlying conditions [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Genital ulcerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genital ulcerations have been linked to
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         therapy, and it is suspected that a topical toxic effect of the drug concentrated in urine is responsible [
         <a href="#rid1">
          1
         </a>
         ]. These lesions are reversible and potentially preventable with careful urinary hygiene.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia has been reported commonly in patients with AIDS receiving
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         , but, again, it is difficult to discern the degree of drug effect. Neutropenia, in contrast to the experience with
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         , is uncommon with foscarnet therapy [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Nausea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infusion-related nausea afflicts about a quarter of persons receiving
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ]. This problem, combined with the requirement for concomitant hydration and need for electrolyte monitoring, make this drug more difficult to administer than
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         .
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          USE IN PREGNANCY AND DURING BREASTFEEDING
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no adequate studies of the safety of
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         in pregnant women, and animal studies have suggested a risk of fetal skeletal abnormalities. In addition, it is not known whether foscarnet is secreted in human milk, although in lactating rats, the concentration in milk is higher than in blood. Thus, foscarnet should only be used in pregnant or breastfeeding patients if the anticipated benefits clearly exceed the potential risks [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1563820">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism of action
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         is a pyrophosphate analog that inhibits viral replication by selectively binding to viral DNA polymerase. (See
         <a class="local">
          'Mechanism of action'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spectrum of activity
         </strong>
         –
         <strong>
         </strong>
         In vitro,
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         inhibits the replication of multiple herpes family viruses, hepatitis B virus, and HIV. Clinically, foscarnet is used almost exclusively to treat patients with cytomegalovirus (CMV) infections, particularly when
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         cannot be used, and acyclovir-resistant herpes simplex virus (HSV) and varicella zoster virus (VZV). (See
         <a class="local">
          'Spectrum of activity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiviral resistance
         </strong>
         –
         <strong>
         </strong>
         Unlike
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         does not require intracellular phosphorylation for antiviral activity; thus, thymidine kinase mutations in HSV or VZV and UL97 phosphotransferase mutations in CMV do not confer drug resistance to foscarnet. (See
         <a class="local">
          'Antiviral resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basic pharmacokinetics
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          Foscarnet
         </a>
         has poor oral bioavailability and is therefore administered intravenously. Clearance decreases with impaired renal function; dose adjustment of foscarnet is required. (See
         <a class="local">
          'Basic pharmacokinetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         –
         <strong>
         </strong>
         The most important adverse effects of
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         are decreased renal function, electrolyte abnormalities, and infusion-related nausea. (See
         <a class="local">
          'Toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Renal insufficiency
         </strong>
         –
         <strong>
         </strong>
         The development of renal insufficiency on
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         is common among AIDS patients taking foscarnet, although renal impairment is usually reversible among patients with previously normal renal function. (See
         <a class="local">
          'Renal insufficiency'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Electrolyte abnormalities
         </strong>
         –
         <strong>
         </strong>
         Hypocalcemia is a well-established effect of
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         , possibly via complex formation between the drug and free calcium. Hypomagnesemia is also common and may contribute to the development of both hypocalcemia and hypokalemia. (See
         <a class="local">
          'Electrolyte abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy and lactation
         </strong>
         –
         <strong>
         </strong>
         There are no adequate studies of the safety of
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         in pregnant women, and animal studies have suggested a risk of fetal skeletal abnormalities. In addition, it is not known whether foscarnet is secreted in human milk. Thus, foscarnet should only be used in pregnant or breastfeeding patients if the anticipated benefits clearly exceed the potential risks. (See
         <a class="local">
          'Use in pregnancy and during breastfeeding'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan BH. Cytomegalovirus Treatment. Curr Treat Options Infect Dis 2014; 6:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agut H, Bonnafous P, Gautheret-Dejean A. Update on infections with human herpesviruses 6A, 6B, and 7. Med Mal Infect 2017; 47:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Page AK, Jager MM, Iwasenko JM, et al. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 2013; 56:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregg K, Hakki M, Kaul DR. UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease. Transpl Infect Dis 2014; 16:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piret J, Boivin G. Antiviral drug resistance in herpesviruses other than cytomegalovirus. Rev Med Virol 2014; 24:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer PR, Matsuura SE, Zonarich D, et al. Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 2003; 77:6127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172:951.
          </a>
         </li>
         <li class="breakAll">
          Astra Arcus. Foscarnet international prescribing information. March 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trifillis AL, Cui X, Drusano GL. Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro. Antimicrob Agents Chemother 1993; 37:2496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998; 32:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldfarb DS, Coe FL. Foscarnet crystal deposition and renal failure. Am J Kidney Dis 1998; 32:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philipponnet C, Michel PA, Daudon M, et al. Intravascular foscarnet crystal precipitation causing multiorgan failure. Am J Kidney Dis 2015; 65:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1991; 1:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989; 9:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro JF, Quereda C, Quereda C, et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 1996; 27:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farese RV Jr, Schambelan M, Hollander H, et al. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann Intern Med 1990; 112:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaman MM, Burney S, Landman D, Quale JM. Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet. Clin Infect Dis 1996; 22:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brady RC, Bernstein DI. Treatment of herpes simplex virus infections. Antiviral Res 2004; 61:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwan LP, Mok MM, Choy BY, Chan TM. Acute kidney injury in a renal transplant recipient due to concomitant use of vancomycin and foscarnet. Nephrology (Carlton) 2017; 22:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillaume MP, Karmali R, Bergmann P, Cogan E. Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS. Clin Infect Dis 1997; 25:932.
          </a>
         </li>
         <li class="breakAll">
          Foscavir- foscarnet sodium injection, solution: Prescribing information. Clinigen Healthcare Ltd. http://labeling.pfizer.com/ShowLabeling.aspx?id=6521 (Accessed on January 20, 2023).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8288 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7527325" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25999800" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cytomegalovirus Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27773488" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Update on infections with human herpesviruses 6A, 6B, and 7.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23243176" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24621186" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24604770" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antiviral drug resistance in herpesviruses other than cytomegalovirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12743270" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7561215" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7561215" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8285643" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9740154" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Identification of crystals in kidneys of AIDS patients treated with foscarnet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9740173" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Foscarnet crystal deposition and renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25301103" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Intravascular foscarnet crystal precipitation causing multiorgan failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1912406" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2554731" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Foscarnet nephrotoxicity: mechanism, incidence and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8604715" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2160217" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8838205" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14670580" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Treatment of herpes simplex virus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28921753" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acute kidney injury in a renal transplant recipient due to concomitant use of vancomycin and foscarnet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9356819" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
